Cocrystal Pharma Inc
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
COCP$1.03-6.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
For the three months ended March 31, 2025 and 2024
(in thousands)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2024 | 10,174 | $10 | $342,931 | $(333,418) | $9,523 |
| Stock-based compensation | - | - | 82 | 82 | |
| Net loss | - | - | - | (2,301) | (2,301) |
| Balance as of March 31, 2025 | 10,174 | $10 | $343,013 | $(335,719) | $7,304 |
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2023 | 10,174 | $10 | $342,288 | $(315,914) | $26,384 |
| Stock-based compensation | - | - | 157 | - | 157 |
| Net loss | - | - | - | (3,956) | (3,956) |
| Balance as of March 31, 2024 | 10,174 | $10 | $342,445 | $(319,870) | $22,585 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.